Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of UCB0942 in highly drug-resistant focal epilepsy
2015-001268-20Phase 2Completed
- Sponsor
- UCB
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of padsevonil in Focal Onset Epilepsy, sponsored by UCB. Primary endpoint: 75% responder rate at end of evaluation period. Started Jul 2015; status: completed.
02
Drugs
padsevonil
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2015-001268-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001268-20.